Retinal Vein Occlusion Market Report and Forecast 2024-2032

Retinal Vein Occlusion Market Outlook

The retinal vein occlusion market size was valued at USD 12.4 billion in 2023, driven by the rising incidence of geriatric population. The market is expected to grow at a CAGR of 13.03% during the forecast period of 2024-2032, with the values likely to rise from USD 14 billion in 2024 to USD 37.2 billion by 2032.

Retinal Vein Occlusion: Introduction

Retinal vein occlusion is a condition characterized by the blockage of small veins carrying blood away from the retina. It may induce sudden blurring or vision loss in one part or the entire eye. Retinal vein occlusion is caused by hardening of veins (atherosclerosis) and blood clot formation. The venous blockage can be broadly divided into two categories, namely, central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). Treatment includes anti-vascular endothelial growth factor injections or focal laser procedures among others. The treatment may vary from patient to patient.

Retinal Vein Occlusion Market Analysis

With the increasing prevalence of sedentary lifestyle and obesity, the incidence of atherosclerosis, also known as hardening of the arteries, has increased. Atherosclerosis is one of the major causes of retinal vein occlusion along with other risk factors like diabetes, high blood pressure, macular edema, and glaucoma. The growing occurrence of these factors has fueled the retinal vein occlusion market demand.

Retinal vein occlusion management has been a key area of attention amongst the researchers. With the rising number of drug approvals for disease management, the market value is anticipated to grow in the forecast period. In October 2023, FDA approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of retinal vein occlusion, based on two phase III studies showcasing early and persistent vision improvements in patients with the condition.

The retinal vein occlusion market growth is driven by the advent of new diagnostic and management tools for facilitating better understanding of the pathophysiology of the disease. Multimodal imaging techniques such as optical coherence tomography (OCT), optical coherence tomography angiography, choroidal imaging and fundus fluorescein angiography are commonly used diagnostic methods.

Retinal Vein Occlusion Market Segmentation

Market Breakup by Type

• Branch Retinal Artery Occlusion

• Central Retinal Vein Occlusion

Market Breakup by Condition

• Non-Ischemic

• Ischemic

Market Breakup by Diagnosis

• Optical Coherence Tomography (OCT)

• Fundoscopic Examination

• Fluorescein Angiography

• Others

Market Breakup by Treatment Type

• Antivascular Endothelial Growth Factor

• Corticosteroid Drugs

• Laser Retinal Photocoagulation

• Others

Market Breakup by End User

• Hospitals

• Clinics

• Ambulatory Surgical Centers

• Homecare Settings

• Others

Market Breakup by Region 

• United States

• EU-4 and the United Kingdom 
  • Germany 
  • France 
  • Italy 
  • Spain 
  • United Kingdom

• Japan

Retinal Vein Occlusion Market Overview

The retinal vein occlusion market share has been dominated by the United States in the historical period. The presence of key healthcare companies can be considered as a major factor fueling the market size. With a robust healthcare infrastructure, scientists can easily integrate numerous technical advancements into their research and develop effective treatment alternatives for the patients.

In Europe, the population is at a higher risk of retinal vein occlusion largely due to high geriatric population. Identifying the risk, the government has been proactive in providing the right awareness to the people. Moreover, the region has been witnessing mergers and acquisitions amongst MedTech companies to expand their product portfolio and cater to the market demand.

Retinal Vein Occlusion Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Allergan

• Bayer AG

• IRIDEX Corporation

• Lumenis

• Novartis AG

• F. Hoffmann-La Roche Ltd

• Regeneron Pharmaceuticals

• Regeneron Pharmaceuticals

• Merck & Co.

• Carl Zeiss

• AbbVie Inc.

• CalciMedica Inc.

• Outlook Therapeutics, Inc.

• Kodiak Sciences Inc.

• Aerie Pharmaceuticals Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report